Researchers assessed the outcomes of all patients admitted to University of Alabama at Birmingham Medical Center from 2005 to 2008 to determine whether antimicrobial use was associated with increased risk or incidence of VRE bloodstream infections.
They found prior-month usage of the antibiotics piperacillin-tazobactam, ceftazidime, cefepime, cefazolin or vancomycin was not predictive of VRE bloodstream infection. However use of antimicrobial ceftriaxone in the prior month was associated with increased incidence of VRE bloodstream infection. Researchers concluded lower use of this type of antimicrobial may improve infection prevention efforts.
Related Articles on Antimicrobial Stewardship:
Antimicrobial Stewardship Programs Reduce CDI Rates, Healthcare Costs
Antimicrobial Resistance to Common UTI Drug Increases 5-Fold
FDA Takes Steps to Foster Judicious Antimicrobial Use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
